ASH 2019 | Ibrutinib maintenance in MCL
Jeremy Abramson
• 7 Dec 2019
Jeremy Abramson, MD, Massachusetts General Hospital Cancer Center, Boston, MA, outlines the preliminary results of a multicenter phase II trial assessing the efficacy and safety of ibrutinib maintenance for mantle cell lymphoma (MCL) after frontline induction. Results show ibrutinib maintenance is feasible in MCL patients who respond to frontline chemoimmunotherapy with or without transplant consolidation. Dr Abramson mentions that a longer follow-up is needed to assess clinical relevance of ibrutinib maintenance and the importance of measurable residual disease (MRD) status. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
